Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

• Lisa A. King,
• Roeland Lameris,
• Tanja D. de Gruijl,
• Hans J. van der Vliet,
• Hans J. van der Vliet

Affiliations

Lisa A. King

Department of Medical Oncology, VU University Medical Center and Cancer Center Amsterdam, Amsterdam, Netherlands

Roeland Lameris

Department of Medical Oncology, VU University Medical Center and Cancer Center Amsterdam, Amsterdam, Netherlands

Tanja D. de Gruijl

Department of Medical Oncology, VU University Medical Center and Cancer Center Amsterdam, Amsterdam, Netherlands

Hans J. van der Vliet

Department of Medical Oncology, VU University Medical Center and Cancer Center Amsterdam, Amsterdam, Netherlands

Hans J. van der Vliet

Lava Therapeutics, Den Bosch, Netherlands